Understanding and Managing Pregnancy in Patients with Lupus

Autoimmune Diseases

Volumn 2015, Issue , 2015, Pages

  De Jesus, Guilherme Ramires ^a   Mendoza Pinto, Claudia ^b,c   De Jesus, Nilson Ramires ^a   Dos Santos, Flavia Cunha ^a   Klumb, Evandro Mendes ^a   Carrasco, Mario Garcia ^b,c   Levy, Roger Abramino ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RO ANTIBODY;

CEREBROVASCULAR ACCIDENT; CONCEPTION; CONTRACEPTION; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE EXACERBATION; ECHOGRAPHY; FETUS OUTCOME; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HIGH RISK PREGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY THERAPY; LABORATORY TEST; LASER DOPPLER FLOWMETRY; LUPUS ERYTHEMATOSUS NEPHRITIS; MATERNAL DISEASE; MATERNAL HYPERTENSION; MATERNAL MORTALITY; MORBIDITY; MOTHER; NEONATAL LUPUS SYNDROME; NEWBORN DISEASE; OBSTETRICIAN; PATIENT CARE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM;

EID: 84938117655     PISSN: 20900422     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2015/943490     Document Type: Review

References (126)

1. A. Lateef and M. Petri, "Managing lupus patients duringpregnancy, " Best Practice and Research: Clinical Rheumatology, vol. 27, no. 3, pp. 435-447, 2013.
2. M. E. B. Clowse, "Lupus activity in pregnancy, " RheumaticDisease Clinics of North America, vol. 33, no. 2, pp. 237-252, 2007.
3. E. Peart and M. E. B. Clowse, "Systemic lupus erythematosusand pregnancy outcomes: an update and review of the literature, "Current Opinion in Rheumatology, vol. 26, no. 2, pp. 118-123, 2014.
4. C. A. Clark, K. A. Spitzer, and C. A. Laskin, "Decrease in pregnancyloss rates in patients with systemic lupus erythematosusover a 40-year period, " Journal of Rheumatology, vol. 32, no. 9, pp. 1709-1712, 2005.
5. E. Vinet, J. Labrecque, C. A. Pineau et al., "A populationbasedassessment of live births in women with systemic lupuserythematosus, " Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 557-559, 2012.
6. R. Andrade, M. L. Sanchez, G. S. Alarcón et al., "Adverse pregnancyoutcomes in women with systemic lupus erythematosusfrom a multiethnic US cohort: LUMINA (LVI) [corrected], "Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 268-274, 2008.
7. M. E. B. Clowse, L. S. Magder, F. Witter, and M. Petri, "Theimpact of increased lupus activity on obstetric outcomes, "Arthritis and Rheumatism, vol. 52, no. 2, pp. 514-521, 2005.
8. M. D. Lockshin, "Pregnancy does not cause systemic lupuserythematosus to worsen, " Arthritis & Rheumatism, vol. 32, no. 6, pp. 665-670, 1989.
9. G. Ruiz-Irastorza, F. Lima, J. Alves et al., "Increased rate of lupusflare during pregnancy and the puerperium: a prospective studyof 78 pregnancies, " British Journal of Rheumatology, vol. 35, no. 2, pp. 133-138, 1996.
10. M. E. B. Clowse, L. S. Magder, F. Witter, and M. Petri, "Early riskfactors for pregnancy loss in lupus, " Obstetrics and Gynecology, vol. 107, no. 2, pp. 293-299, 2006.
11. K.-L. Wong, F.-Y. Chan, and C.-P. Lee, "Outcome of pregnancyin patients with systemic lupus erythematosus. A prospectivestudy, " Archives of Internal Medicine, vol. 151, no. 2, pp. 269-273, 1991.
12. A. W. Shand, C. S. Algert, L. March, and C. L. Roberts, "Second pregnancy outcomes for women with systemic lupuserythematosus, " Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 547-551, 2013.
13. K. T. Jørgensen, B. V. Pedersen, N. M. Nielsen, S. Jacobsen, and M. Frisch, "Childbirths and risk of female predominantand other autoimmune diseases in a population-based Danishcohort, " Journal of Autoimmunity, vol. 38, no. 2-3, pp. J81-J87, 2012.
14. M. Ostensen and M. Clowse, "Pathogenesis of pregnancy complicationsin systemic lupus erythematosus, " Current Opinion inRheumatology, vol. 25, no. 5, pp. 591-596, 2013.
15. A. Munoz-Suano, A. B. Hamilton, and A. G. Betz, "Gimmeshelter: the immune system during pregnancy, " ImmunologicalReviews, vol. 241, no. 1, pp. 20-38, 2011.
16. D. W. Bianchi, G. K. Zickwolf, G. J. Weil, S. Sylvester, andM. A. Demaria, "Male fetal progenitor cells persist in maternal bloodfor as long as 27 years postpartum, " Proceedings of the NationalAcademy of Sciences of the United States of America, vol. 93, no. 2, pp. 705-708, 1996.
17. E. Vinet, A. E. Clarke, C. Gordon et al., "Decreased live births inwomen with systemic lupus erythematosus, " Arthritis Care andResearch, vol. 63, no. 7, pp. 1068-1072, 2011.
18. A. Doria, A. Ghirardello, L. Iaccarino et al., "Pregnancy, cytokines, and disease activity in systemic lupus erythematosus, "Arthritis Care & Research, vol. 51, no. 6, pp. 989-995, 2004.
19. M. Stensen, F. Förger, and P. M. Villiger, "Cytokines andpregnancy in rheumatic disease, " Annals of the New YorkAcademy of Sciences, vol. 1069, pp. 353-363, 2006.
20. S. Q. Crome, A. Y. Wang, and M. K. Levings, "Translationalmini-review series on Th17 cells: function and regulation ofhuman T helper 17 cells in health and disease, " Clinical &Experimental Immunology, vol. 159, no. 2, pp. 109-119, 2010.
21. M. H. Nyirenda, L. Sanvito, P. J. Darlington et al., "TLR2stimulation drives human naive and effector regulatory T cellsinto aTh17-like phenotype with reduced suppressive function, "The Journal of Immunology, vol. 187, no. 5, pp. 2278-2290, 2011.
22. A. B. Pernis, "Th17 cells in rheumatoid arthritis and systemiclupus erythematosus, " Journal of InternalMedicine, vol. 265, no. 6, pp. 644-652, 2009.
23. E. Bettelli, M. Oukka, and V. K. Kuchroo, "T-17 cells in thecircle of immunity and autoimmunity, "Nature Immunology, vol. 8, no. 4, pp. 345-350, 2007.
24. V. Saini, S. Arora, A. Yadav, and J. Bhattacharjee, "Cytokines inrecurrent pregnancy loss, " Clinica Chimica Acta, vol. 412, no. 9-10, pp. 702-708, 2011.
25. A. Doria, L. Iaccarino, P. Sarzi-Puttini et al., "Estrogens inpregnancy and systemic lupus erythematosus, " Annals of theNew York Academy of Sciences, vol. 1069, pp. 247-256, 2006.
26. M. Cutolo, A. Sulli, S. Capellino et al., "Sex hormones influenceon the immune system: basic and clinical aspects in autoimmunity, "Lupus, vol. 13, no. 9, pp. 635-638, 2004.
27. P. Conti, D. Kempuraj, K. Kandere et al., "IL-10, an inflammatory/inhibitory cytokine, but not always, " Immunology Letters, vol. 86, no. 2, pp. 123-129, 2003.
28. R. K. ChowdaryVenigalla, T. Tretter, S. Krienke et al., "ReducedCD4+, CD25-T cell sensitivity to the suppressive function ofCD4+, CD25, CD127/regulatory T cells in patients withactive systemic lupus erythematosus, " Arthritis & Rheumatism, vol. 58, no. 7, pp. 2120-2130, 2008.
29. C. Tower, I. Crocker, D. Chirico, P. Baker, and I. Bruce, "SLEand pregnancy: the potential role for regulatory T cells, " NatureReviews Rheumatology, vol. 7, no. 2, pp. 124-128, 2011.
30. S. Björkander, K. Bremme, J.-O. Persson, R. F. van Vollenhoven, E. Sverremark-Ekström, and U. Holmlund, "Pregnancyassociatedinflammatory markers are elevated in pregnantwomen with systemic lupus erythematosus, " Cytokine, vol. 59, no. 2, pp. 392-399, 2012.
31. T. Andersen, L. Munthe-Fog, P. Garred, and S. Jacobsen, "Serumlevels of ficolin-3 (Hakata antigen) in patients with systemiclupus erythematosus, " Journal of Rheumatology, vol. 36, no. 4, pp. 757-759, 2009.
32. A. Halmos, J. Rigó, J. Szijártó, G. Füst, Z. Prohászka, and A. Molvarec, "Circulating ficolin-2 and ficolin-3 in normal pregnancyand pre-eclampsia, " Clinical & Experimental Immunology, vol. 169, no. 1, pp. 49-56, 2012.
33. D. Andrade, M. Kim, L. P. Blanco et al., "Interferon-andangiogenic dysregulation in pregnant lupus patients destinedfor preeclampsia, " Arthritis & Rheumatology, vol. 67, no. 4, pp. 977-987, 2015.
34. S. Minamiguchi, Y. Mikami, N. Nakajima et al., "Complementsplit product C4d deposition in placenta in systemic lupus erythematosusand pregnancy-induced hypertension, " PathologyInternational, vol. 63, no. 3, pp. 150-157, 2013.
35. D. N. Burns, P. Nourjah, D. J. Wright et al., "Changes in immuneactivation markers during pregnancy and postpartum, " Journalof Reproductive Immunology, vol. 42, no. 2, pp. 147-165, 1999.
36. L. Jara-Quezada, A. Graef, and C. Lavalle, "Prolactin andgonadal hormones during pregnancy in systemic lupus erythematosus, "Journal of Rheumatology, vol. 18, no. 3, pp. 349-353, 1991.
37. A. Leanos-Miranda, G. Cárdenas-Mondragón, A. Ulloa-Aguirre, I. Isordia-Salas, A. Parra, and J. Ramrez-Peredo, "Anti-prolactin autoantibodies in pregnant women withsystemic lupus erythematosus: maternal and fetal outcome, "Lupus, vol. 16, no. 5, pp. 342-349, 2007.
38. A. Doria, A. Tincani, and M. Lockshin, "Challenges of lupuspregnancies, " Rheumatology, vol. 47, supplement 3, pp. iii9-iii12, 2008.
39. C.-S. Yee, M. Akil, M. Khamashta et al., "The BILAG2004-pregnancy index is reliable for assessment of disease activity inpregnant SLE patients, " Rheumatology, vol. 51, no. 10, pp. 1877-1880, 2012.
40. G. Ruiz-Irastorza andM. A. Khamashta, "Lupus andpregnancy:integrating clues fromthe bench and bedside, " European Journalof Clinical Investigation, vol. 41, no. 6, pp. 672-678, 2011.
41. E. Imbasciati, A. Tincani, G. Gregorini et al., "Pregnancy inwomen with pre-existing lupus nephritis: predictors of fetal andmaternal outcome, " Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 519-525, 2009.
42. M. E. B. Clowse, L. S. Magder, andM. Petri, "The clinical utilityof measuring complement and anti-dsDNA antibodies duringpregnancy in patients with systemic lupus erythematosus, "Journal of Rheumatology, vol. 38, no. 6, pp. 1012-1016, 2011.
43. E. Borella, A. Lojacono, M. Gatto et al., "Predictors of maternaland fetal complications in SLE patients: a prospective study, "Immunologic Research, vol. 60, no. 2-3, pp. 170-176, 2014.
44. H. Yang, H. Liu, D. Xu et al., "Pregnancy-related systemic lupuserythematosus: clinical features, outcome and risk factors ofdisease flares-a case control study, " PLoS ONE, vol. 9, no. 8, Article ID e104375, 2014.
45. T. J. Stanhope, W. M. White, K. G. Moder, A. Smyth, and V. D. Garovic, "Obstetric nephrology: lupus and lupus nephritisin pregnancy, " Clinical Journal of the American Society ofNephrology, vol. 7, no. 12, pp. 2089-2099, 2012.
46. S. M. Ramin, A. C. Vidaeff, E. R. Yeomans, and L. C. Gilstrap III, "Chronic renal disease in pregnancy, " Obstetrics & Gynecology, vol. 108, no. 6, pp. 1531-1539, 2006.
47. E. M. Klumb, L. M. S. Barros, L. Romeiro, N. R. de Jesús, R. A. Levy, and E. M. N. Albuquerque, "The impact of nephritis ongestational results in women with systemic lupus erythematosus, "Revista Brasileira de Reumatologia, vol. 45, no. 3, pp. 107-113, 2005.
48. K. Bramham, B. J. Hunt, S. Bewley et al., "Pregnancy outcomesin systemic lupus erythematosus with and without previousnephritis, " Journal of Rheumatology, vol. 38, no. 9, pp. 1906-1913, 2011.
49. C. K. Li and D. A. Isenberg, "Systemic lupus erythematosus, "Medicine, vol. 34, no. 11, pp. 445-452, 2006.
50. A. Smyth, G. H. M. Oliveira, B. D. Lahr, K. R. Bailey, S. M. Norby, and V. D. Garovic, "A systematic review and metaanalysisof pregnancy outcomes in patients with systemic lupuserythematosus and lupus nephritis, " Clinical Journal of theAmerican Society of Nephrology, vol. 5, no. 11, pp. 2060-2068, 2010.
51. J. P. Buyon, "Updates on lupus and pregnancy, " Bulletin of theNYU Hospital for Joint Diseases, vol. 67, no. 3, pp. 271-275, 2009.
52. K. P. Conradand J. M. Davison, "The renal circulationinnormalpregnancy and preeclampsia: is there a place for relaxin" TheAmerican Journal of Physiology-Renal Physiology, vol. 306, no. 10, pp. F1121-F1135, 2014.
53. M. A. Saavedra, C. Cruz-Reyes, O. Vera-Lastra et al., "Impact ofprevious lupus nephritis onmaternal and fetal outcomes duringpregnancy, " Clinical Rheumatology, vol. 31, no. 5, pp. 813-819, 2012.
54. R. Fischer-Betz, C. Specker, R. Brinks, M. Aringer, and M. Schneider, "Low risk of renal flares and negative outcomes inwomen with lupus nephritis conceiving after switching frommycophenolate mofetil to azathioprine, " Rheumatology, vol. 52, no. 6, pp. 1070-1076, 2013.
55. F. Z. Rahman, J. Rahman, S. A. Al-Suleiman, and M. S. Rahman, "Pregnancy outcome in lupus nephropathy, " Archivesof Gynecology and Obstetrics, vol. 271, no. 3, pp. 222-226, 2005.
56. E. Oviasu, J. Hicks, and J. S. Cameron, "The outcome ofpregnancy in women with lupus nephritis, " Lupus, vol. 1, no. 1, pp. 19-25, 1991.
57. G. Moroni, S. Quaglini, G. Banfi et al., "Pregnancy in lupusnephritis, " American Journal of Kidney Diseases, vol. 40, no. 4, pp. 713-720, 2002.
58. M. E. Clowse, M. Jamison, E. Myers, and A. H. James, "Anational study of the complications of lupus in pregnancy, " TheAmerican Journal of Obstetrics & Gynecology, vol. 199, no. 2, pp. 127. e1-127. e6, 2008.
59. E. M. Klumb, C. A. Silva, C. C. Lanna et al., "Consensus of theBrazilian Society of Rheumatology for the diagnosis, managementand treatment of lupus nephritis, " Revista Brasileira deReumatologia, vol. 55, no. 1, pp. 1-21, 2015.
60. T. K. Chen, A. C. Gelber, F. R. Witter, M. Petri, andD. M. Fine, "Renal biopsy in the management of lupus nephritis duringpregnancy, " Lupus, vol. 24, no. 2, pp. 147-154, 2015.
61. R. J. Levine, S. E. Maynard, C. Qian et al., "Circulating angiogenicfactors and the risk of preeclampsia, " The New EnglandJournal of Medicine, vol. 350, no. 7, pp. 672-683, 2004.
62. G. de Jesus, N. de Jesus, R. Levy, and E. Klumb, "The use ofangiogenic and antiangiogenic factors in the differential diagnosisof pre-eclampsia, antiphospholipid syndrome nephropathyand lupus nephritis, " Lupus, vol. 23, no. 12, pp. 1299-1301, 2014.
63. G. R. de Jesus, C. S. Oliveira, F. C. Santos et al., "Angiogenicand antiangiogenic factors in patients with systemic lupuserythematosus, " Arthritis&Rheumatology, vol. 66, supplement, p. S1157, 2014.
64. C. E. Kleinrouweler, M. M. J. Wiegerinck, C. Ris-Stalpers etal., "Accuracy of circulating placental growth factor, vascularendothelial growth factor, soluble fms-like tyrosine kinase 1and soluble endoglin in the prediction of pre-eclampsia: asystematic review and meta-analysis, " BJOG, vol. 119, no. 7, pp. 778-787, 2012.
65. C. Oakley and C. A. Warnes, Heart Disease in Pregnancy, Blackwell Publishing, Malden, Mass, USA, 2nd edition, 2007.
66. M. Bonnin, F. J. Mercier, O. Sitbon et al., "Severe pulmonaryhypertension during pregnancy: mode of delivery and anestheticmanagement of 15 consecutive cases, " Anesthesiology, vol. 102, no. 6, pp. 1133-1137, 2005.
67. P. Lin, E. Rhew, R. B. Ness et al., "Adverse pregnancy outcomesand subsequent risk of cardiovascular disease in women withsystemic lupus erythematosus, " Lupus Science & Medicine, vol. 1, no. 1, Article ID e000024, 2014.
68. J. E. Salmon, C. Heuser, M. Triebwasser et al., "Mutations incomplement regulatory proteins predispose to preeclampsia: agenetic analysis of the PROMISSE cohort, " PLoS Medicine, vol. 8, no. 3, Article ID e1001013, 2011.
69. A. Tincani, C. Bazzani, S. Zingarelli, and A. Lojacono, "Lupusand the antiphospholipid syndrome in pregnancy and obstetrics:clinical characteristics, diagnosis, pathogenesis, and treatment, "Seminars in Thrombosis and Hemostasis, vol. 34, no. 3, pp. 267-273, 2008.
70. J. A. Gómez-Puerta, G. Espinosa, and R. Cervera, "Catastrophicantiphospholipid syndrome: diagnosis and management inpregnancy, " Clinics in Laboratory Medicine, vol. 33, no. 2, pp. 391-400, 2013.
71. M. Stensen, L. Andreoli, A. Brucato et al., "State of the art:reproduction and pregnancy in rheumatic diseases, " AutoimmunityReviews, vol. 14, no. 5, pp. 376-386, 2015.
72. J. Alijotas-Reig, R. Ferrer-Oliveras, A. Ruffatti et al., "TheEuropean Registry on Obstetric Antiphospholipid Syndrome(EUROAPS): a survey of 247 consecutive cases, " AutoimmunityReviews, vol. 14, no. 5, pp. 387-395, 2015.
73. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, "GAPSS: the global anti-phospholipidsyndromescore, " Rheumatology, vol. 52, no. 8, Article IDket388, pp. 1397-1403, 2013.
74. C. A. Clark, K. A. Spitzer, J. N. Nadler, and C. A. Laskin, "Preterm deliveries in women with systemic lupus erythematosus, "Journal of Rheumatology, vol. 30, no. 10, pp. 2127-2132, 2003.
75. M. J. Johnson, M. Petri, F. R. Witter, and J. T. Repke, "Evaluationof preterm delivery in a systemic lupus erythematosuspregnancy clinic, " Obstetrics and Gynecology, vol. 86, no. 3, pp. 396-399, 1995.
76. S. Y. Yuen, A. Krizova, J. M. Ouimet, and J. E. Pope, "Pregnancyoutcome in systemic lupus erythematosus (SLE) is improving:Results from a case control study and literature review, " TheOpen Rheumatology Journal, vol. 2, no. 1, pp. 89-98, 2009.
77. M. S. Magid, C. Kaplan, L. R. Sammaritano, M. Peterson, M. L. Druzin, and M. D. Lockshin, "Placental pathology in systemiclupus erythematosus: a prospective study, " The American Journalof Obstetrics and Gynecology, vol. 179, no. 1, pp. 226-234, 1998.
78. K. Lun Hon and A. K. C. Leung, "Neonatal lupus erythematosus, "AutoimmuneDiseases, vol. 2012, Article ID301274, 6 pages, 2012.
79. P. M. Izmirly, M. Y. Kim, C. Llanos et al., "Evaluation ofthe risk of anti-SSA/Ro-SSB/La antibody-associated cardiacmanifestations of neonatal lupus in fetuses of mothers withsystemic lupus erythematosus exposed to hydroxychloroquine, "Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1827-1830, 2010.
80. P. M. Izmirly, C. Llanos, L. A. Lee, A. Askanase, M. Y. Kim, and J. P. Buyon, "Cutaneous manifestations of neonatal lupusand risk of subsequent congenital heart block, " Arthritis andRheumatism, vol. 62, no. 4, pp. 1153-1157, 2010.
81. D. M. Friedman, M. Y. Kim, J. A. Copel, C. Llanos, C. Davis, and J. P. Buyon, "Prospective evaluation of fetuses withautoimmune-associated congenital heart block followed in thePR Interval and Dexamethasone Evaluation (PRIDE) study, "The American Journal of Cardiology, vol. 103, no. 8, pp. 1102-1106, 2009.
82. A. J. J. T. Rein, D. Mevorach, Z. Perles et al., "Early diagnosisand treatment of atrioventricular block in the fetus exposed tomaternal anti-SSA/Ro-SSB/La antibodies a prospective, observational, fetal kinetocardiogram-based study, " Circulation, vol. 119, no. 14, pp. 1867-1872, 2009.
83. J. P. Buyon, R. M. Clancy, and D. M. Friedman, "Cardiacmanifestations of neonatal lupus erythematosus: guidelines tomanagement, integrating clues from the bench and bedside, "Nature Clinical Practice Rheumatology, vol. 5, no. 3, pp. 139-148, 2009.
84. E. T. Jaeggi, J.-C. Fouron, E. D. Silverman, G. Ryan, J. Smallhorn, and L. K. Hornberger, "Transplacental fetal treatment improvesthe outcome of prenatally diagnosed complete atrioventricularblock without structural heart disease, " Circulation, vol. 110, no. 12, pp. 1542-1548, 2004.
85. P. M. Izmirly, N. Costedoat-Chalumeau, C. N. Pisoni et al., "Maternal use of hydroxychloroquine is associated with areduced risk of recurrent anti-SSA/ro-antibody-associatedcardiac manifestations of neonatal lupus, " Circulation, vol. 126, no. 1, pp. 76-82, 2012.
86. R. D. Tunks, M. E. B. Clowse, S. G. Miller, L. R. Brancazio, andP. C. A. Barker, "Maternal autoantibody levels in congenital heartblock and potential prophylaxis with antiinflammatory agents, "American Journal of Obstetrics & Gynecology, vol. 208, no. 1, pp. 64. e1-64. e7, 2013.
87. D. M. Friedman, C. Llanos, P. M. Izmirly et al., "Evaluation offetuses in a study of intravenous immunoglobulin as preventivetherapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial, " Arthritis and Rheumatism, vol. 62, no. 4, pp. 1138-1146, 2010.
88. C. N. Pisoni, A. Brucato, A. Ruffatti et al., "Failureof intravenousimmunoglobulin to prevent congenital heart block: findings ofa multicenter, prospective, observational study, " Arthritis andRheumatism, vol. 62, no. 4, pp. 1147-1152, 2010.
89. J. G. Routsias, N. C. Kyriakidis, D. M. Friedman et al., "Associationof the idiotype: antiidiotype antibody ratio with the efficacyof intravenous immunoglobulin treatment for the preventionof recurrent autoimmune-associated congenital heart block, "Arthritis & Rheumatism, vol. 63, no. 9, pp. 2783-2789, 2011.
90. M. Stensen, "Intravenous immunoglobulin does not preventrecurrence of congenital heart block in children of SSA/Ropositivemothers, " Arthritis and Rheumatism, vol. 62, no. 4, pp. 911-914, 2010.
91. H. Eliasson, S.-E. Sonesson, G. Sharland et al., "Isolated atrioventricularblock in the fetus: a retrospective, multinational, multicenter study of 175 patients, " Circulation, vol. 124, no. 18, pp. 1919-1926, 2011.
92. P. M. Izmirly, A. Saxena, M. Y. Kim et al., "Maternal andfetal factors associated with mortality and morbidity in amulti-racial/ethnic registry of anti-SSA/Ro-associated cardiacneonatal lupus, " Circulation, vol. 124, no. 18, pp. 1927-1935, 2011.
93. G. R. R. de Jesus, F. C. Dos Santos, C. S. Oliveira, W. Mendes-Silva, N. R. de Jesus, and R. A. Levy, "Management of obstetricantiphospholipid syndrome, " Current Rheumatology Reports, vol. 14, no. 1, pp. 79-86, 2012.
94. R. Madazli, M. A. Yuksel, M. Oncul, M. Imamoglu, and H. Yilmaz, "Obstetric outcomes and prognostic factors of lupuspregnancies, " Archives of Gynecology and Obstetrics, vol. 289, no. 1, pp. 49-53, 2014.
95. G. Pagani, R. Reggia, L. Andreoli et al., "The role of secondtrimester uterine artery Doppler in pregnancies with systemiclupus erythematosus, " PrenatalDiagnosis, vol. 35, no. 5, pp. 447-452, 2015.
96. D. Le Thi Huong, B. Wechsler, D. Vauthier-Brouzes et al., "The second trimester Doppler ultrasound examination isthe best predictor of late pregnancy outcome in systemiclupus erythematosus and/or the antiphospholipid syndrome, "Rheumatology, vol. 45, no. 3, pp. 332-338, 2006.
97. B. H. Hahn, M. A. McMahon, A. Wilkinson et al., "AmericanCollege of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, " Arthritis Care andResearch, vol. 64, no. 6, pp. 797-808, 2012.
98. G. K. Bertsias, M. Tektonidou, Z. Amoura et al., "Joint EuropeanLeague Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA)recommendations for the management of adult andpaediatric lupus nephritis, " Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1771-1782, 2012.
99. R. A. Levy, V. S. Vilela, M. J. Cataldo et al., "Hydroxychloroquine(HCQ) in lupus pregnancy: double-blind and placebocontrolledstudy, " Lupus, vol. 10, no. 6, pp. 401-404, 2001.
100. A. Makol, K. Wright, and S. Amin, "Rheumatoid arthritis andpregnancy: safety considerations in pharmacological management, "Drugs, vol. 71, no. 15, pp. 1973-1987, 2011.
101. A. Osadchy, T. Ratnapalan, and G. Koren, "Ocular toxicity inchildren exposed in utero to antimalarial drugs: review of theliterature, " Journal of Rheumatology, vol. 38, no. 12, pp. 2504-2508, 2011.
102. V. Jain and C. Gordon, "Managing pregnancy in inflammatoryrheumatological diseases, " Arthritis Research and Therapy, vol. 13, no. 1, article 206, 2011.
103. R. M. Ward, B. A. Bates, W. E. Benitz et al., "The transfer of drugsand other chemicals into human milk, " Pediatrics, vol. 108, no. 3, pp. 776-789, 2001.
104. J. M. W. Hazes, P. G. Coulie, V. Geenen et al., "Rheumatoidarthritis and pregnancy: evolution of disease activity andpathophysiological considerations for drug use, " Rheumatology, vol. 50, no. 11, pp. 1955-1968, 2011.
105. J. Yazdany, L. Trupin, R. Kaiser et al., "Contraceptive counselingand use among women with systemic lupus erythematosus: agap in health care quality" Arthritis Care and Research, vol. 63, no. 3, pp. 358-365, 2011.
106. E. B. Schwarz and S. Manzi, "Risk of unintended pregnancyamong women with systemic lupus erythematosus, " ArthritisCare & Research, vol. 59, no. 6, pp. 863-866, 2008.
107. K. R. Culwell, K. M. Curtis, andM. delCarmenCravioto, "Safetyof contraceptive method use amongwomenwith systemic lupuserythematosus: a systematic review, " Obstetrics and Gynecology, vol. 114, no. 2, part 1, pp. 341-353, 2009.
108. E. M. Stringer, C. Kaseba, J. Levy et al., "A randomizedtrial of the intrauterine contraceptive device vs hormonalcontraception in women who are infected with the humanimmunodeficiency virus, " The American Journal of Obstetricsand Gynecology, vol. 197, no. 2, pp. 144. e1-144. e8, 2007.
109. M. Cutolo, S. Capellino, and R. H. Straub, "Oestrogens inrheumatic diseases: friend or foe" Rheumatology, vol. 47, supplement 3, pp. iii2-iii5, 2008.
110. J. Sánchez-Guerrero, A. G. Uribe, L. Jiménez-Santana et al., "Atrial of contraceptive methods in women with systemic lupuserythematosus, "The New England Journal of Medicine, vol. 353, no. 24, pp. 2539-2549, 2005.
111. M. Petri, M. Y. Kim, K. C. Kalunian et al., "Combined oralcontraceptives in women with systemic lupus erythematosus, "The New England Journal ofMedicine, vol. 353, no. 24, pp. 2550-2558, 2005.
112. N. Chabbert-Buffet, Z. Amoura, P.-Y. Scarabin et al., "Pregnaneprogestin contraception in systemic lupus erythematosus: alongitudinal study of 187 patients, " Contraception, vol. 83, no. 3, pp. 229-237, 2011.
113. A. M. Kaunitz, R. Arias, and M. McClung, "Bone densityrecovery after depot medroxyprogesterone acetate injectablecontraception use, " Contraception, vol. 77, no. 2, pp. 67-76, 2008.
114. C. J. Hardy, B. P. Palmer, S. J. Morton, K. R. Muir, and R. J. Powell, "Pregnancy outcome and family size in systemic lupuserythematosus: a case-control study, " Rheumatology, vol. 38, no. 6, pp. 559-563, 1999.
115. R. A. Hickman and C. Gordon, "Causes and management ofinfertility in systemic lupus erythematosus, " Rheumatology, vol. 50, no. 9, pp. 1551-1558, 2011.
116. C. A. Silva, E. Bonfa, andM. Stensen, "Maintenance of fertilityin patients with rheumatic diseases needing antiinflammatoryand immunosuppressive drugs, " Arthritis Care & Research, vol. 62, no. 12, pp. 1682-1690, 2010.
117. Z. Blumenfeld, O. Mischari, N. Schultz, N. Boulman, andA. Balbir-Gurman, "Gonadotropin releasing hormone agonistsmay minimize cyclophosphamide associated gonadotoxicityin SLE and autoimmune diseases, " Seminars in Arthritis andRheumatism, vol. 41, no. 3, pp. 346-352, 2011.
118. M. C. Micu, R. Micu, andM. Ostensen, "Luteinized unrupturedfollicle syndrome increased by inactive disease and selectivecyclooxygenase 2 inhibitors in women with inflammatoryarthropathies, " Arthritis Care and Research, vol. 63, no. 9, pp. 1334-1338, 2011.
119. N. Guballa, L. Sammaritano, S. Schwartzman, J. Buyon, andM. D. Lockshin, "Ovulation induction and in vitro fertilization insystemic lupus erythematosus and antiphospholipid syndrome, "Arthritis & Rheumatism, vol. 43, no. 3, pp. 550-556, 2000.
120. L. C. Udoff and D. W. Branch, "Management of patients withantiphospholipid antibodies undergoing in vitro fertilization, "Journal of Autoimmunity, vol. 15, no. 2, pp. 209-211, 2000.
121. A. Levine and M. Lockshin, "Assisted reproductive technologyin SLE and APS, " Lupus, vol. 23, no. 12, pp. 1239-1241, 2014.
122. K. L. Buckingham and L. W. Chamley, "A critical assessment ofthe role of antiphospholipid antibodies in infertility, " Journal ofReproductive Immunology, vol. 80, no. 1-2, pp. 132-145, 2009.
123. C. Coughlan, X. Yuan, T. Nafee, J. Yan, N. Mariee, andT. Li, "Theclinical characteristics of women with recurrent implantationfailure, " Journal of Obstetrics and Gynaecology, vol. 33, no. 5, pp. 494-498, 2013.
124. A. Steinvil, R. Raz, S. Berliner et al., "Association of commonthrombophilias and antiphospholipid antibodies with successrate of in vitro fertilisation, " Thrombosis and Haemostasis, vol. 108, no. 6, pp. 1192-1197, 2012.
125. C. Chighizola and G. de Jesus, "Antiphospholipid antibodiesand infertility, " Lupus, vol. 23, no. 12, pp. 1232-1238, 2014.
126. Practice Committee of American Society for ReproductiveMedicine, "Anti-phospholipid antibodies do not affect IVFsuccess, " Fertility and Sterility, vol. 90, no. 5, supplement, pp. S172-S173, 2008.